The Life Sciences team advised Remedium Bio, Inc. on its multi-target research and development collaboration with Eli Lilly and Company to develop and commercialize gene therapies for obesity and Type 2 diabetes. The collaboration leverages Remedium’s Prometheus™ dose-adjustable gene therapy platform and Lilly’s expertise in metabolic diseases to pursue one-time, subcutaneously administered treatments with long-term efficacy and tunable control of therapeutic protein expression. Under the terms of the agreement, Remedium Bio will receive an upfront payment, equity investment, and potential development and commercialization milestone payments. Remedium is also eligible to receive tiered royalties on worldwide net sales of any resulting products.
Remedium is a biotechnology company developing treatments for large unmet clinical needs. To enable this, the company has developed a revolutionary gene therapy platform, which potentiates safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheus™ platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy at a fraction of the current protein-based therapeutic treatment cost. Remedium’s pipeline includes several disease modifying treatments with unprecedented efficacy in the fields of endocrinology (weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases. Remedium is based in Lilly Gateway Labs, Boston, which is part of the Lilly Catalyze360™ model, a comprehensive approach to empower early-stage biotech startups across all therapeutic areas by providing access to funding as well as world-class lab space and drug development talent and resources through its three pillars: Lilly Ventures, Lilly Gateway Labs®, and Lilly ExploR&D™.
The Goodwin team was led by Sarah Solomon and Emily Beman.
For more information, please read the press release.